Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relenopride

Next Previous
X
Search
Drug Profile

Relenopride

Alternative Names: SKL-IBS; YKP-10811; YKP-GI

Latest Information Update: 26 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK biopharmaceuticals
  • Developer SK biopharmaceuticals; SK Chemicals
  • Class Benzamides; Carbamates; Fluorobenzenes; Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Constipation; Irritable bowel syndrome; Neurological disorders

Most Recent Events

  • 26 Sep 2022 Relenopride is still in phase II trial for Neurological disorders in South Korea (PO) (SK Biopharmaceuticals pipeline, September 2022)
  • 20 Jul 2020 Phase-II clinical trials in Neurological disorders in South Korea (PO) prior to July 2020 ((SK Biopharmaceuticals pipeline, July 2020)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in USA (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top